SGLT2i reduces risk of CV death, heart failure symptoms
Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) results in a lower risk of clinically relevant cardiovascular death, heart failure (HF) hospitalization, and HF symptoms with similar rates of adverse events (AEs), results of a meta-analysis have shown.